Ke Hao, PhD
img_Ke Hao
PROFESSOR | Genetics and Genomic Sciences
Research Topics
Biostatistics, Genetics, Mathematical and Computational Biology
Multi-Disciplinary Training Area
Genetics and Genomic Sciences [GGS]

BS, Tsinghua University

ScD, Harvard University


Selected Publications

Prioritization of potential causative genes for schizophrenia in placenta. Gianluca Ursini, Pasquale Di Carlo, Sreya Mukherjee, Qiang Chen, Shizhong Han, Jiyoung Kim, Maya Deyssenroth, Carmen J. Marsit, Jia Chen, Ke Hao, Giovanna Punzi, Daniel R. Weinberger. Nature Communications

Polygenic risk scores point toward potential genetic mechanisms of type 2 myocardial infarction in people with HIV. Won Jun Lee, Haoxiang Cheng, Bridget M. Whitney, Robin M. Nance, Sierra R. Britton, Kristina Jordahl, Sara Lindstrom, Stephanie A. Ruderman, Mari M. Kitahata, Michael S. Saag, Amanda L. Willig, Greer Burkholder, Joseph J. Eron, Jason C. Kovacic, Johan L.M. Björkegren, W. Christopher Mathews, Edward Cachay, Matthew J. Feinstein, Mathew Budoff, Peter W. Hunt, Richard D. Moore, Jeanne Keruly, Mary E. McCaul, Geetanjali Chander, Allison Webel, Kenneth H. Mayer, Joseph A. Delaney, Paul K. Crane, Claudia Martinez, Heidi M. Crane, Ke Hao, Inga Peter. International Journal of Cardiology

Biopsy and blood-based molecular biomarker of inflammation in IBD. Carmen Argmann, Ruixue Hou, Ryan C. Ungaro, Haritz Irizar, Zainab Al-Taie, Ruiqi Huang, Roman Kosoy, Swati Venkat, Won Min Song, Antonio F. Di'narzo, Bojan Losic, Ke Hao, Lauren Peters, Phillip H. Comella, Gabrielle Wei, Ashish Atreja, Milind Mahajan, Alina Iuga, Prerak T. Desai, Patrick Branigan, Aleksandar Stojmirovic, Jacqueline Perrigoue, Carrie Brodmerkel, Mark Curran, Joshua R. Friedman, Amy Hart, Esi Lamousé-Smith, Jan Wehkamp, Saurabh Mehandru, Eric E. Schadt, Bruce E. Sands, Marla C. Dubinsky, Jean Frederic Colombel, Andrew Kasarskis, Mayte Suárez-Fariñas. Gut

View All Publications

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Hao did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.